is the most promising candidate in this series, with both enhanced cytotoxic activity and favorable docking interactions, suggesting that pyrimidine-thiadiazole hybrids represent a valuable scaffold for further anticancer drug development.
Ghoneim et al. (Sat,) studied this question.